4BB 4basebio PLC

LSE · GB · Healthcare · Biotechnology · 4basebio.com

562.50GBp0.00%Mkt Cap: 94.68M $P/E: —Today

4basebio PLC, together with its subsidiaries, engages in the research, development, manufacturing, and sale of synthetic DNA and RNA products in Europe, the United States, and internationally. It offers hpDNA, a double s…

Industry Peers

Biotechnology

Screen all

VRTX

Vertex Pharmaceuticals Incorporated - Common Stock

$127.85BUSDP/E 29.4

MRNA

Moderna, Inc. - Common Stock

$75.86BUSD

REGN

Regeneron Pharmaceuticals, Inc. - Common Stock

$75.69BUSDP/E 18.2

ARGX

argenx SE - American Depositary Shares

Revolution Medicines, Inc. - Common Stock

BeOne Medicines Ltd. - American Depositary Shares

$40.51BUSDP/E 63.9

RPRX

Royalty Pharma plc - Class A Ordinary Shares

$33.03BUSDP/E 30.7

ALNY

Alnylam Pharmaceuticals, Inc. - Common Stock

$29.40BUSDP/E 38.3

ROIV

Roivant Sciences Ltd. - Common Shares

$25.80BUSD

BNTX

BioNTech SE - American Depositary Shares

$24.34BUSD

INSM

Insmed Incorporated - Common Stock

$24.27BUSD

INCY

Incyte Corporation - Common Stock

Genmab A/S - American Depositary Shares

$21.69BUSDP/E 27.4

JAZZ

Jazz Pharmaceuticals plc - Ordinary Shares

$15.30BUSDP/E 16.1

ASND

Ascendis Pharma A/S - Ordinary Share

$14.99BUSDP/E 17.8

EXEL

Exelixis, Inc. - Common Stock

$14.47BUSDP/E 18.4

SMMT

Summit Therapeutics Inc. - Common Stock

$13.37BUSD

Key Statistics

Company

Market Cap94.68M USD

Enterprise Value104.85M USD

Revenue (TTM)848.91K USD

Gross Profit1.06M USD

Net Income (TTM)-18.38M USD

Revenue/Share0.05 GBp

Last Price562.50 GBp

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees140

CountryGB

SectorHealthcare

IndustryBiotechnology

ISIN—

Valuation

P/E (Trailing)—

P/E (Forward)-6.62

PEG—

EV/EBITDA-5.92

EV/Revenue123.51

P/S111.53

P/B8.64

EPS (TTM)-1.16

EPS (Forward)-0.85

52W Range

0.000066% of range850.00

52W High850.00 GBp

52W Low0.0000 GBp

Profitability

Gross Margin57.53%

Oper. Margin-3385.88%

EBITDA Margin0.00%

Profit Margin-998.52%

ROE-167.19%

ROA-57.21%

Growth

Revenue Growth-77.70%

Earnings Growth—

Cash Flow & Leverage

Operating CF-16.94M USD

CapEx (TTM)1.78M USD

FCF Margin-1621.72%

FCF Yield-14.54%

Net Debt9.85M USD

Net Debt/EBITDA-0.56

Balance Sheet

Debt/Equity1.65

Current Ratio5.98

Quick Ratio5.17

Book Value/Sh0.65 GBp

Cash/Share0.90 GBp

Dividends

Fwd Div Rate—

Trail. Div Rate0.00 GBp

Div. Yield0.00%

5Y Avg Yield—

Payout Ratio—

Ex-Div Date—

Pay Date—

Analyst Consensus

Rating1.5 (Buy)

Strong BuyBuyHoldSellStr. Sell

Target (Mean)1400.00 GBp

Upside (mean)+148.9%

Target Range1000.00 GBp – 1800.00 GBp

1000.00+148.9% to mean1800.00

# Analysts2

Ownership

Shares Out.15.48M

Float5.74M

Insiders60.56%

Institutions14.17%

Technical

SMA 50509.23 (+10.5%)

SMA 200525.11 (+7.1%)

Beta0.86

S&P 52W Chg14.58%

Avg Vol (30d)1.45K

Avg Vol (10d)3.00K

Technical Indicators

RSI (14)80.0

MACD18.5160

MACD Signal11.6138

MACD Hist.+6.9022

BB Upper600.89 GBp

BB Middle516.00 GBp

BB Lower431.11 GBp

BB Width32.90%

ATR (14)30.40 GBp

Vol Ratio (20d)0.51x